Advertisements



Celsion says OVATION 1 study shows strong PFS survival treatment effect

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 26th, 2020

UNC researchers highlgiht promising signs for cancer treatment, still work to be done

A recent review of cancer survival rates over 30 years shows significant improvement in key areas – but researchers at UNC Chapel Hill found the improvement was largely absent from certain kinds of cancers. According to a new study in the Jour.....»»

Category: topSource: bizjournalsMar 3rd, 2020

Celsion announces progression-free survival data from OVATION I study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 24th, 2018

Celsion announces initial results from Phase I of Phase I/II OVATION 2 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 19th, 2020

Study shows strong recognition rates for Bucks patch sponsor Harley-Davidson, but will HOG renew?

New patch deals could be worth at least 30% more than when the original sponsorships were sold three seasons ago......»»

Category: topSource: bizjournalsFeb 25th, 2020

Guardant says study shows Guardant360 effectively guides oncology treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 13th, 2019

Merck KGaA, Pfizer drug fails to meet endpoints in gastric cancer trial

Merck KGaA and Pfizer said Friday that a late-stage clinical trial testing Bavencio as a first-line maintenance treatment for patients with certain forms of gastric cancer failed to meet the study's primary endpoints for survival. The cur.....»»

Category: topSource: marketwatchNov 8th, 2019

Report shows that private equity contributes billions in tax dollars for Texas

The private equity industry is not only employing millions, but it’s also contributing billions of dollars in taxes, a report shows.  The study was conducted by EY in partnership with the American Investment Council, and shows the effect that.....»»

Category: topSource: bizjournalsNov 5th, 2019

Jaguar Health says study shows Mytesi may support diarrhea treatment in cancer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2019

Study on Abiomed"s Impella shows increased survival in cardiogenic shock

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 27th, 2019

Medivir AB - Interim Report January - June 2019

STOCKHOLM, Aug. 28, 2019 /PRNewswire/ -- April – June Significant events during the quarter Selective effect signal on liver cancer tissue in phase Ia study with MIV-818. The analysis shows an early indication tha.....»»

Category: earningsSource: benzingaAug 28th, 2019

Allena says "substantial" treatment effect observed in reloxaliase study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 4th, 2019

Merck"s Keytruda no better than chemo as a first-line treatment for gastric cancer, according to Phase 3 study results

Merck & Co. Inc. said Friday that a Phase 3 trial evaluating Keytruda as a first-line treatment for gastric cancer failed to show improvement in patients' overall or progression-free survival when compared with chemotherapy. Shares of th.....»»

Category: topSource: marketwatchApr 26th, 2019

New Chronic Migraine Treatment Works for Those Failed by Other Drugs, Study Shows

Erenumab was found to reduce the average number of migraines by 50 percent or more......»»

Category: topSource: newsweekApr 17th, 2018

Jonathan Aberman: We know noncitizen workers have huge role in local economy. A new study shows just how much.

A study on the role of non-U.S. citizens in our region’s work force was released last week by the Center for Regional Analysis at George Mason University. At a time when a lot of emotion surrounds the treatment of immigrants, I valued the opportu.....»»

Category: topSource: bizjournalsJun 7th, 2018

Weight Loss Treatment Could One Day Turn "Bad" White Fat Into "Good" Brown Fat, Study Shows

Brown fat burns more energy than white fat......»»

Category: topSource: newsweekJun 11th, 2018

Australian researchers find no evidence that cannabis helps with chronic pain

An Australian study of 1,500 people revealed no strong findings supporting the use of cannabis in the treatment of chronic non-cancer pain. The study published in the journal Lancet P.....»»

Category: topSource: businessinsiderJul 2nd, 2018

Early results boost hopes for historic gene editing attempt

Early, partial results from a historic gene editing study give encouraging signs that the treatment may be safe and having at least some of its hoped-for effect, but it's too soon to know whether it ultimately will succeed......»»

Category: topSource: foxnewsSep 5th, 2018

Celsion initiates dosing patients in OVATION II Study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 6th, 2018

Is Halloween a good time to invest in stocks? One study looking back 300 years say yes

‘The 62,962 monthly observations over 323 years show a strong Halloween effect.’.....»»

Category: topSource: marketwatchOct 31st, 2018

Merck"s Keytruda Improves Survival in Esophageal Cancer Study

Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer. Merck & Co., Inc. MRK annou.....»»

Category: dealsSource: nytNov 15th, 2018